

Mathai Mammen

Chairman, CEO, & President, Parabilis Medicines

Mathai Mammen, M.D., Ph.D., is Chairman, CEO, and President of Parabilis Medicines, a biopharmaceutical company pioneering therapies for previously “undruggable” protein targets for patients with serious diseases. Under Mathai’s leadership, Parabilis has established a differentiated portfolio of potentially transformational medicines targeting disease-driving biology long considered out of reach, including zolucateide (previously FOG-001), the first and only inhibitor of the elusive β -catenin:TCF interaction, and promising discovery-stage assets targeting ERG and allosteric ARON in prostate cancer – together reflecting the Helicon™ platform’s ability to repeatedly engage high-difficulty targets. Under Mathai’s leadership, Parabilis has established a differentiated portfolio of potentially transformational medicines targeting disease-driving biology long considered out of reach, including zolucateide (previously FOG-001), the first and only inhibitor of the elusive β -catenin:TCF interaction, and promising discovery-stage assets targeting ERG and allosteric ARON in prostate cancer – together reflecting the Helicon platform’s ability to repeatedly engage high-difficulty targets. Previously, Mathai served as Global Head of R&D and a member of the Executive Committee at Johnson & Johnson. There, he led and evolved one of the world’s largest pharmaceutical R&D organizations and spearheaded the strategic integration of data science and AI across the portfolio. During his tenure, his team secured global approvals for nine medicines including Tremfya™, Darzalex Faspro™, Carvykti™, Tecvayli™, and Spravato™ and achieved an unprecedented 90% success rate in Phase 2 to Phase 3 transitions. He also oversaw 40+ acquisitions and licenses, , including the acquisition of Inlexzo™, along with 350+ strategic partnerships that expanded J&J’s portfolio and capabilities. Before J&J, Mathai was SVP at Merck, contributing to the development of Keytruda™ and the discovery of enlitenide, and earlier co-founded Theravance, Inc., where he led R&D toward five approved therapies including Breo™, Anoro™, and Trelegy™. In total, he has led the discovery/development of 19 approved medicines. He serves on the boards of Sandoz, Xaira, Kelonia, and GBH, and is an advisor to General Atlantic and Foresite Capital. He holds an M.D. from Harvard/MIT (HST) and a Ph.D. from Harvard University.